Neurology

Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing

Approval based on Phase 3 NIMBLE results demonstrating rapid, deep and sustained disease control that is maintained throughout three-month dosing...

Cancer Research UK and Dewpoint Therapeutics partner to advance potential first-in-class MYC condensate modulator into clinical development

DPTX8743 is a potential first-in-class small molecule modulator of MYC condensates, targeting one of cancer’s most important and historically undruggable...

FDA approves Roche’s Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer

Wilserdly is the first and only next-generation all-oral SERD combination to significantly outperform standard endocrine combination in a post-CDK4/6 inhibitor...

CervoMed Presents Interim Data at CTAD 2026 Showing Neflamapimod Reduces Neurodegeneration Biomarker in Nonfluent Variant Primary Progressive Aphasia

24-Week interim data shows neflamapimod delivered an exposure-dependent reduction in neurofilament light chain, a key biomarker of neuronal damage  Full...

New Jersey-based Shore Medical Center and Shore Physicians Group Select Oracle Health’s New AI-Powered EHR to Create a More Connected Experience for Patients and Care Teams

Technology will unify Shore Medical Center and Shore Physicians Group to streamline care, improve communication, and enhance the patient experienceAUSTIN,...

New Jersey-based Shore Medical Center and Shore Physicians Group Select Oracle Health’s New AI-Powered EHR to Create a More Connected Experience for Patients and Care Teams

Technology will unify Shore Medical Center and Shore Physicians Group to streamline care, improve communication, and enhance the patient experienceAUSTIN,...

CNS Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Progress in Establishing Transformative Therapeutic Pipeline

Company has been exploring multiple acquisition and licensing opportunities, with the goal of securing first transaction by year-end$17.2 million cash...

Arexera Therapeutics Highlights Potentially Best-in-Class Preclinical Profile and Initiates Clinical Development for ATL-101 in Huntington’s Disease

– ATL-101 achieved robust (~80%) and durable (> 6 months after single administration) HTT lowering in the striatum, the key...

Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses

FDA IND clearance opens a new era for Oculis in neurology, initiating clinical development in acute MS relapses by building...

Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses

FDA IND clearance opens a new era for Oculis in neurology, initiating clinical development in acute MS relapses by building...

Roche presents new data across pharmaceuticals and diagnostics from its growing Alzheimer’s disease portfolio at CTAD 2026

Updated Phase Ib/IIa Brainshuttle™ AD study data for trontinemab demonstrating rapid amyloid removal dynamics and changes in key biomarkers Phase III...

Tiziana KOL Call Highlights Consistency Between Positive Phase 2a INFORM-MS Topline Results and Longer-Term Clinical Benefits Observed in Expanded Access Program for Patients with Non-Active Secondary Progressive Multiple Sclerosis Treated with Intranasal Foralumab

error: Content is protected !!